Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Staschak S et al. | A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. | 1990 | Transplant. Proc. | pmid:1689896 |
Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. | 1990 | Transplant. Proc. | pmid:1689897 | |
Cadoff EM et al. | Assay of FK 506 in plasma. | 1990 | Transplant. Proc. | pmid:1689898 |
Venkataramanan R et al. | Pharmacokinetics of FK 506: preclinical and clinical studies. | 1990 | Transplant. Proc. | pmid:1689899 |
Jain AB et al. | Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. | 1990 | Transplant. Proc. | pmid:1689900 |
Fung JJ et al. | Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. | 1990 | Transplant. Proc. | pmid:1689901 |
Zeevi A et al. | Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. | 1990 | Transplant. Proc. | pmid:1689902 |
Imventarza O et al. | Renal transplantation in baboons under FK 506. | 1990 | Transplant. Proc. | pmid:1689903 |
Monden M et al. | A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. | 1990 | Transplant. Proc. | pmid:1689904 |
Ericzon BG et al. | Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. | 1990 | Transplant. Proc. | pmid:1689905 |
Starzl TE et al. | Kidney transplantation under FK 506. | 1990 | JAMA | pmid:1693970 |
Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
Maki N et al. | Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1695378 |
Doe SE et al. | Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. | 1990 | Biochem. Soc. Trans. | pmid:1695581 |
Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Standaert RF et al. | Molecular cloning and overexpression of the human FK506-binding protein FKBP. | 1990 | Nature | pmid:1696686 |
Hara S et al. | The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. | 1990 | Clin. Immunol. Immunopathol. | pmid:1700936 |
Murase N et al. | Effect of FK 506 on spontaneous diabetes in BB rats. | 1990 | Diabetes | pmid:1700959 |
Kawashima H and Mochizuki M | Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. | 1990 | Exp. Eye Res. | pmid:1701148 |
Siekierka JJ et al. | The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. | 1990 | J. Biol. Chem. | pmid:1701173 |
Johansson A and Möller E | Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. | 1990 | Transplantation | pmid:1701570 |
Reyes J et al. | Expressive dysphasia possibly related to FK506 in two liver transplant recipients. | 1990 | Transplantation | pmid:1701571 |
Tsuji RF et al. | Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. | 1990 | J. Antibiot. | pmid:1701765 |
Granelli-Piperno A et al. | The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. | 1990 | J. Exp. Med. | pmid:1701825 |
Lee KK et al. | Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. | 1990 | Transplant. Proc. | pmid:1702239 |
Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |
Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
Jorgensen WL | Rusting of the lock and key model for protein-ligand binding. | 1991 | Science | pmid:1719636 |
Kobayashi N et al. | Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. | 1991 | Transplant. Proc. | pmid:1703707 |
Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
Strasser S et al. | The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. | 1991 | Transplant. Proc. | pmid:1703709 |
Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
Ryu S and Yasunami Y | Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. | 1991 | Transplant. Proc. | pmid:1703710 |
Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
Ito T et al. | The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. | 1991 | Transplant. Proc. | pmid:1703716 |
Sumpio BE and Phan S | Nephrotoxic potential of FK 506. | 1991 | Transplant. Proc. | pmid:1721278 |
Pichard L et al. | Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. | 1991 | Transplant. Proc. | pmid:1721279 |
Christians U et al. | Interactions of FK 506 and cyclosporine metabolism. | 1991 | Transplant. Proc. | pmid:1721280 |
Wu YM et al. | Interaction between FK 506 and cyclosporine in dogs. | 1991 | Transplant. Proc. | pmid:1721281 |
Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
Su MS and Semerjian A | Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. | 1991 | Transplant. Proc. | pmid:1721310 |
Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
Wang SC et al. | FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. | 1991 | Transplant. Proc. | pmid:1721312 |
Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
Uemoto S et al. | Experience with FK 506 in living related donor liver transplantation. | 1991 | Transplant. Proc. | pmid:1721342 |
Tzakis AG et al. | FK 506 versus cyclosporine in pediatric liver transplantation. | 1991 | Transplant. Proc. | pmid:1721343 |
Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
de Paulis A et al. | Characterization of the anti-inflammatory effect of FK-506 on human mast cells. | 1991 | J. Immunol. | pmid:1721644 |
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721374 | |
Christians U et al. | Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. | 1991 | Transplant. Proc. | pmid:1703358 |
Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
Lieberman KV et al. | FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). | 1991 | Transplant. Proc. | pmid:1721376 |
Demetris AJ et al. | Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703360 |
Ueda D et al. | Influence of FK 506 on renal blood flow. | 1991 | Transplant. Proc. | pmid:1721377 |
Thomson AW et al. | The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. | 1991 | Transplant. Proc. | pmid:1703361 |
Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
Adams CK and Famili P | A study of the effects of the drug FK 506 on gingival tissues. | 1991 | Transplant. Proc. | pmid:1721405 |
Pirsch JD et al. | Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721406 |
Shinozuka H et al. | Effect of FK 506 on experimental liver carcinogenesis. | 1991 | Transplant. Proc. | pmid:1721407 |
Pelekanou V et al. | FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. | 1991 | Transplant. Proc. | pmid:1721408 |
Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
Michnick SW et al. | Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. | 1991 | Science | pmid:1709301 |
Van Duyne GD et al. | Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. | 1991 | Science | pmid:1709302 |
Ito T et al. | Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. | 1991 | Transplant. Proc. | pmid:1721437 |
DeValeria PA et al. | FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. | 1991 | Transplant. Proc. | pmid:1721438 |
Jiang H et al. | Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. | 1991 | Transplant. Proc. | pmid:1721439 |
Sato K et al. | Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. | 1991 | Transplant. Proc. | pmid:1721440 |
Katayama Y et al. | Immunosuppressive effects of FK 506 in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1721441 |
Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
Takada K et al. | Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. | 1991 | J. Pharmacobio-dyn. | pmid:1713626 |
Jin YJ et al. | Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1713687 |
Nicoletti F et al. | FK-506 prevents diabetes in diabetes-prone BB/Wor rats. | 1991 | Int. J. Immunopharmacol. | pmid:1722192 |
Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
Granelli-Piperno A and McHugh P | Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1722332 |
Nelson PA et al. | cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. | 1991 | Gene | pmid:1722474 |
Chen MF et al. | The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. | 1991 | Immunol. Lett. | pmid:1722778 |
Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |